Article Sidebar

PDF
Date Published: 16/05/2023
Abstract Views: 491
Views PDF: 105
DOI: https://doi.org/10.51298/vmj.v526i1A.5292
Issue
Vol. 526 No. 1A (2023)
Section
Các bài báo
How to Cite
Đỗ, H. K. ., & Nguyễn, V. T. . (2023). ASSESSING THE PRELIMINARY RESULT OF INDUCTION TCF-REGIMEN CHEMOTHERAPY IN LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER. Vietnam Medical Journal, 526(1A). https://doi.org/10.51298/vmj.v526i1A.5292

ASSESSING THE PRELIMINARY RESULT OF INDUCTION TCF-REGIMEN CHEMOTHERAPY IN LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER

Hùng Kiên Đỗ1,, Văn Tài Nguyễn1
1 k hospital

Main Article Content

Abstract

Objective: Assessing treatment response and analysing several factors affecting response rate of induction TCF-regimen chemotherapy in patients with locally advanced squamous cell head and neck cancer at K Hospital. Patients and method: Retrospective and prospective analysis of 47 patients with locally advanced squamous cell head and neck cancer who were treated with induction TCF-regimen chemotherapy at K Hospital from January 2019 to December 2022. Results: Of 47 patients, majority of patients were male (74.5%) with age < 65 years old (68.1%). ECOG performance status 0 was reported in 38.3%. Stage IV (M0) was observed in 78.7%. Hypolaryngeal and laryngeal cancers were observed in 44.7%, then oropharyngeal cancer (accounted for 34%). Overall response rate of induction TCF-regimen chemotherapy was seen in 70.2%. Conclusion: Induction TCF-regimen chemotherapy for the treatment of locally advanced squamous cell head and neck cancer had a high overall response rate.

Article Details

Keywords

squamous cell head and neck cancer, locally advanced, induction chemotherapy, TCF

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021, 71, 209–249, doi:10.3322/ caac.21660.
2. Nguyễn Văn Hiếu. Ung thư học. Nhà xuất bản Y học, 2015.
3. Posner, M.R.; Hershock, D.M.; Blajman, C.R.; Mickiewicz, E.; Winquist, E.; Gorbounova, V.; Tjulandin, S.; Shin, D.M.; Cullen, K.; Ervin, T.J.; et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. N Engl J Med 2007, 357, 1705–1715, doi:10.1056/NEJMoa070956.
4. Vermorken, J.B.; Remenar, E.; van Herpen, C.; Gorlia, T.; Mesia, R.; Degardin, M.; Stewart, J.S.; Jelic, S.; Betka, J.; Preiss, J.H.; et al. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. N Engl J Med 2007, 357, 1695–1704, doi:10.1056/ NEJMoa071028.
5. National comprehensive Cancer network (NCCN) NCCN Practice Guideline for Head and Neck Cancer, Version 2022; 2022;
6. Gau, M.; Karabajakian, A.; Reverdy, T.; Neidhardt, E.-M.; Fayette, J. Induction Chemotherapy in Head and Neck Cancers: Results and Controversies. Oral Oncology 2019, 95, 164–169, doi:10.1016/j.oraloncology.2019.06.015.